The ground truth for drug discovery
We measure real interactions between real molecules, on the hardest targets and the most complex modalities.
Who we help
For the targets and molecules that stall discovery
We work with discovery teams with hard targets, AI drug discovery companies, and teams developing complex modalities such as molecular glues, degraders and PPI inhibitors.
- Hard targetsScreening and characterisation from micrograms of protein, for targets that are scarce, unstable or hard to make.
- AI-designed moleculesBinding measured directly for each design: which bind, how strongly and how selectively, with data to feed back into the models.
- Complex modalitiesComplexes formed by glues and degraders, or disrupted by PPI inhibitors: observed directly and without labels.
- Co-developmentJoint programmes that pair partners’ biology with our chemistry and platform.
Discovery engine
Make. Identify. Optimise.
From primary screen to lead optimisation.
- Make. Your compounds or AI-designed molecules, screened one at a time or thousands at once.
- Identify. What binds, detected directly by its exact mass, from micrograms of protein: free of labels, immobilisation and custom assays.
- Optimise. What binds shapes the next library, round after round, through to the characterisation of analogue series.
Proof points
Proven on hard targets
Case 01 / 04
PROTAC-induced ternary complex
One measurement resolves every species in the mixture: KRAS G12C, free and covalently bound to the PROTAC LC-2; the VHL E3 ligase complex and its subunits; and the 68.3 kDa ternary complex, which forms only with the PROTAC.
Case 02 / 04
Kir4.2 ion channel
A screen of 2,000 natural products, multiplexed in pools of 100, identified a new Kir4.2 binder: ginsenoside Rg1. A control protein showed no binding to the same compounds. The channel’s known agonist, polymyxin B, added to one pool as a control, was also identified.
Gu et al., ACS Chem. Biol. 2024 · doi:10.1021/acschembio.3c00781
Case 03 / 04
Highly multiplexed screening
Macrocycle pools from 20 to more than 160,000 compounds were screened against the E3 ligase KEAP1. The binders found match the amino acid sequences recognised by KEAP1 in vivo, including ETGE and ESGE, plus further variants. Without the ligase, nothing was found.
Case 04 / 04
TRPM2 ion channel
A screen of 2,000 natural products, multiplexed in pools of 100, identified a new TRPM2 binder by its exact mass: ginsenoside F3. The known inhibitor clotrimazole was also identified. A control off-target protein showed no binding to the same compounds.
Gu et al., ChemBioChem 2024 · doi:10.1002/cbic.202300790
Our pipeline
Our own programmes in endometriosis
One in ten women of reproductive age live with it, yet there is no cure. We apply our platform to our own discovery pipeline, and we’re open to partners.
- Target-led discoveryFirst-in-class programmes on prioritised endometriosis targets, progressing hits towards lead compounds.
- Patient-biology-led discoveryStarting from patient tissue, to uncover new disease-driving targets and the patients most likely to benefit.
Contact
Bring us your hardest target
Whether you have a target to screen, hits to confirm, or a question your assays can’t answer, a short call is usually enough to say whether we can help, and how fast.